SBIR/STTR Research Award
Zebrafish: A Whole Animal Model for Target Validation
Award amount
$155,764Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHYLONIX PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Angiogenesis is a complex process that
plays a pivotal role in several human diseases, including cancers. A number of
genes involved in vessel formation and maintenance have been identified and
their functions characterized in a number of vertebrate species, including
humans. Because the functions of many of these genes are conserved, animal
models have been successfully used to study angiogenesis and identify genes
involved in these processes. However, until recently, effective strategies for
selectively repressing expression of specific genes and determining function
have been limited to a few model organisms. This Phase I SBIR aims to develop
the zebrafish as a model organism for angiogenesis target validation using a
novel 'reverse genetics' approach. This approach can be used to examine the
role of novel genes in angiogenesis as well as vessel maintenance. In addition,
this approach may prove useful in generating gene 'knock down' in highly
vascularized organs. The long-term goal of this project is to develop this
approach as a tool for identifying the function of uncharacterized genes and
evaluating their potential as therapeutic targets.
PROPOSED COMMERCIAL APPLICATION:
By providing a method for identifying angiogenesis targets, the zebrafish assay will
facilitate the drug development process for cancer and heart disease.
Technology keywords
Not reported